Novartis reports good news from COVID-19 antiviral trial
The pharma firm and collaborator Molecular Partners reported positive data out of their Phase II study for ensovibep, an antiviral for treating the virus.
Archives for January 12, 2022
NervGen Pharma sets sights on trial for spinal-cord injury treatment
The company plans to launch a Phase Ib/II study of its compound NVG-291 in collaboration with researchers at Northwestern University’s Shirley Ryan AbilityLab.